Logo

Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Share this

Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Shots:

  • The approval is based on P-III JAVELIN Bladder 100 study assessing Bavencio (10 mg/kg- IV infusion- q2w) + BSC vs BSC as monothx. in 700 patients with LA/ m-UC whose disease had not progressed after 1L platinum-based induction CT as per RECIST v1.1
  • Results: median OS (7.1 vs 21.4mos.); improvement in OS represents a 31% reduction in the risk of death in the overall population- in PD-L1+ patients (44% reduction in risk of death)- in an exploratory analysis of patients with PD L1 negative tumors- OS hazard ratio (0.85)
  • Priority review of the therapy was completed under FDA’s Real-Time Oncology Review (RTOR) pilot program- following the receipt of BT designation. In 2017- the US FDA approved the therapy under the accelerated approval program and now converted it to a full approval

Click here to read full press release/ article 

Ref: Pfizer | Image: Merck KGaA


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions